article thumbnail

Japanese drugmakers make greener packaging pledge

pharmaphorum

Four Japanese drugmakers – Astellas, Eisai, Daiichi Sankyo, and Takeda – have joined forces in a partnership intended to reduce the environmental impact of pharmaceutical packaging. The post Japanese drugmakers make greener packaging pledge appeared first on.

Packaging 105
article thumbnail

STAT+: Congress explores changes to the way Medicare pays doctors

STAT

At a hearing Thursday, lawmakers in both parties talked about overhauling a 2015 law that aimed to shift physicians toward so-called value based payment models, rather than the traditional fee-for-service system. Congress is taking early steps towards changing the way Medicare pays physicians.

Packaging 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Tackling fake pharmaceuticals: an industry united against counterfeit products

European Pharmaceutical Review

These may be mislabelled or produced in fake packaging and, most dangerously, there is no regulation around their manufacture. According to the latest WHO estimates in 2015, this duped consumer base accounts for 50 percent of all online drug purchases. Supply-chain visibility.

Packaging 104
article thumbnail

Citrate-free HCF of adalimumab biosimilar gets positive opinion

European Pharmaceutical Review

As part of the submission package to the EMA, Sandoz conducted a Phase I pharmacokinetics (PK) bridging study comparing its approved adalimumab 50mg/ml with the 100mg/ml (HCF). In 2015, the EMA and US Food and Drug Administration (FDA) approved Humira ® HCF, which contains adalimumab at a concentration of 100mg/ml.

article thumbnail

Common pharma compliance concerns cited by FDA warning letters

European Pharmaceutical Review

However, the researchers noted that a larger number of warning letters were issued to pharmaceutical manufacturers (ie, by CDER) than to medical device manufacturers (by CDRH) between 2015 and 2020. The major reasons for this were poor cGMP compliance and misbranding.

FDA 105
article thumbnail

FDA approves over-the-counter naloxone

The Checkup by Singlecare

The Narcan nasal spray, manufactured by Emergent BioSolutions, wasn’t granted FDA approval until 2015—but access was restricted to those with a prescription. This delay allows time for manufacturing changes for nonprescription packaging and supply chain modifications. chief medical officer of Toolbox Genomics.

FDA 98
article thumbnail

Enabling the leaders of the future

pharmaphorum

iii] It’s no longer just about the company, compensation package and secondary benefits (e.g., He joined the company in 2015, moving to the position of head of HR medical devices North America in 2019, before taking up his current role in 2021. gym membership).